| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:SB357134
CAS:219963-52-7
Package:50mg/RMB 13800;100mg/RMB 17500;25mg/RMB 10600
|
SB-357134 manufacturers
- SB357134
-
- $1980.00 / 50mg
-
2026-05-11
- CAS:219963-52-7
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | SB-357134 Basic information |
| Product Name: | SB-357134 | | Synonyms: | SB-357134;Benzenesulfonamide, N-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-(1-piperazinyl)- | | CAS: | 219963-52-7 | | MF: | C17H18Br2FN3O3S | | MW: | 523.21 | | EINECS: | | | Product Categories: | | | Mol File: | 219963-52-7.mol |  |
| | SB-357134 Chemical Properties |
| Boiling point | 607.1±65.0 °C(Predicted) | | density | 1.701±0.06 g/cm3(Predicted) | | pka | 6.12±0.10(Predicted) |
| | SB-357134 Usage And Synthesis |
| Uses | SB-357134 is a potent, selective, brain penetrant, and orally active 5-HT6 receptor antagonist. SB-357134 enhances memory and learning and increases seizure threshold in rats[1]. | | in vivo | SB-357134 dose-dependently inhibits the specific [125I]SB-258585 binding[1].
SB-357134 (0.03-30 mg/kg; 0-24 h; p.o.; single dose) produces a potent and dose-related anticonvulsant effect in the rat MEST model, with a minimum significantly effective dose of 0.1 mg/kg[1].
Chronic administration of SB-357134 (10 mg/kg; p.o.; twice daily; 7 days) significantly shortens path length compared to vehicle and acute administration of SB-357134[1]. | Animal Model: | Sprague–Dawley rats[1] | | Dosage: | 0.03–30 mg/kg | | Administration: | 0-24 h; p.o.; 0.03–30 mg/kg | | Result: | Produced a potent and dose-related anticonvulsant effect in the rat MEST model, with a minimum significantly effective dose of 0.1 mg/kg. Increased seizure threshold up to 123±12% at the highest dose tested of 30 mg/kg. At 10 mg/kg, exhibited a rapid onset of action, significantly increasing seizure threshold from a control value of 21.7 to 26.7 mA at 1 h postdose. Observed Peak activity within 4–6 h postdose. With the exception of an unexplained loss of activity at 12 h, had a long duration of action of 21 h in this model. |
| Animal Model: | Sprague–Dawley rats[1] | | Dosage: | 10 mg/kg | | Administration: | 10 mg/kg; p.o.; twice daily; 7 days | | Result: | Significantly shortened path length when administered chronically compared to vehicle and administered acutely. |
| | References | [1] Stean TO, et al. Pharmacological profile of SB-357134: a potent, selective, brain penetrant, and orally active 5-HT(6) receptor antagonist. Pharmacol Biochem Behav. 2002 Apr;71(4):645-54. DOI:10.1016/s0091-3057(01)00742-0 |
| | SB-357134 Preparation Products And Raw materials |
|